With the development of human society and economy, people's demand for improving the quality of life is becoming more and more urgent. Alzheimer's disease (AD) and other senile diseases, characterized by memory decline, seriously affect people's quality of life, bring heavy economic and psychological burdens to the family and society, and also contribute to social development and the construction of a socialist harmonious society. bring adverse effects, therefore, drugs for the treatment of memory loss will have broad market prospects.

On June 12, Wanbangde Pharmaceutical Group and Shanghai Institute of Materia Medica, Chinese Academy of Sciences signed a strategic cooperation agreement on the "Alzheimer's New Drug FN12" project. Since then, Wanbangde Pharmaceutical Group will invest heavily in cooperation with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences to jointly complete the clinical and registration work of the "New Alzheimer's Disease Drug FN12".

The new drug for Alzheimer's disease, FN12, is a new drug developed by Shanghai Institute of Materia Medica for the pathogenesis of Alzheimer's disease through years of efforts. Effects on memory, cognition, and behavioral function in patients.